Imatinib Mesylate (Gleevec/Glivec/STI571)

January 5, 2007. An open letter from Novartis regarding the Glivec legal challenge in India. Word (World) to Novartis: drop lawsuit over Indian patent law.

February 6, 2003. Korean Leukemia patients arrested while trying to meet with Novartis.

January, 2006 - Indian Patent Office Rules Novartis Patent Invalid

General Information

Imatinib mesylate was once knows as STI571 but is now sold by Novartis as "Gleevec" in the United States and as "Glivec" elsewhere. It is FDA-approved for two rare forms of cancer: chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Patients prescribed the drug typically take four 100mg capsulse a day.

Attempt for Compulsory License for Glivec in Korea



Research and Development

Glivec International Patient Assistance Program (GIPAP)

Dispute Over Exclusive Marketing Rights for Glivec in India

News Stories, General

Return to: CPTech Home -> Main IP Page -> IP and Healthcare